| Bioactivity | PPARδ agonist 9 (compound 21) is a PPARδ agonist (EC50: 3.6 nM). PPARδ agonist 9 has in vivo efficacy, reducing serum levels of MCP-1 in mice and significantly inhibiting atherosclerosis progression in the LDLr-KO model (inhibition rate: 50-60%)[1]. |
| Target | EC50:3.6 nM (PPARδ) |
| Name | PPARδ agonist 9 |
| CAS | 928023-21-6 |
| Formula | C26H28ClF3N4O3S |
| Molar Mass | 569.04 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kato T, et al. Design, Synthesis, and Anti-Inflammatory Evaluation of a Novel PPARδ Agonist with a 4-(1-Pyrrolidinyl)piperidine Structure. J Med Chem. 2023 Aug 24;66(16):11428-11446.. |
PPARδ agonist 9
CAS: 928023-21-6 F: C26H28ClF3N4O3S W: 569.04
PPARδ agonist 9 (compound 21) is a PPARδ agonist (EC50: 3.6 nM). PPARδ agonist 9 has in vivo efficacy, reducing serum
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.